Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeff Gonzalez

Gastroenterology Hialeah, FL Medical Doctor

NPI 1548241169 CMS profile 251081

2140 W 68Th St, Suite 300, Hialeah, FL 33016

Open in the dashboard

General payments

$5,948

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$167,580 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Jeff Gonzalez of Hialeah, FL is reported in the CMS Open Payments database as having received $5,948 across 348 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $167,580 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $905 46
2024 General $1,039 58
2023 General $1,254 76
2022 General $603 29
2021 General $946 56
2020 General $430 23
2019 General $772 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeff Gonzalez
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jeff Gonzalez were reported at $905. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jeff Gonzalez Gastroenterology median Middle half National median
2019 $772 $417 $126–$1,100 $163
2020 $430 $224 $74–$624 $114
2021 $946 $352 $106–$1,054 $132
2022 $603 $448 $129–$1,270 $149
2023 $1,254 $533 $150–$1,390 $160
2024 $1,039 $605 $160–$1,606 $164
2025 $905 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,471 77 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $922 82 payments
  3. Intercept Pharmaceuticals, Inc. $642 28 payments
  4. Ironwood Pharmaceuticals, Inc $345 28 payments
  5. RedHill Biopharma Inc. $330 18 payments
  6. Ardelyx, Inc. $254 14 payments
  7. Pfizer Inc. $190 10 payments
  8. Braintree Laboratories, Inc. $174 9 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $160 8 payments
  10. Ipsen Biopharmaceuticals, Inc $136 5 payments
  11. Other $1,324 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,948 348 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $666 57 payments
  2. HUMIRA $465 23 payments
  3. OCALIVA $440 18 payments
  4. RINVOQ $439 20 payments
  5. LINZESS Gastroenterology $372 24 payments
  6. SKYRIZI $364 15 payments
  7. Talicia $330 18 payments
  8. Linzess Gi $329 27 payments
  9. CREON $313 16 payments
  10. IBSRELA $254 14 payments
  11. Other $2,866 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

827

Median for Internal Medicine: 777

Drug cost

$104,042

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 18 $47,861
Linzess Linaclotide Brand 47 $28,833
Trulance Plecanatide Brand 12 $6,673
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 63 $3,715
Mesalamine Generic 19 $3,502
Mesalamine Er Mesalamine Brand 16 $2,711
Famotidine Generic 139 $2,146
Omeprazole Generic 162 $2,117
Hyoscyamine Sulfate Generic 31 $1,838
Pantoprazole Sodium Generic 224 $1,589

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$19,717

Medicare's payments for the services billed

Medicare patients

94

Average age 73

Services billed

161

64 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 51%
Ischemic heart disease 44%
Depression 43%
COPD 38%
Chronic kidney disease 32%
Osteoporosis 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
  • Ironwood Pharmaceuticals, Inc $223
  • AbbVie, Inc. $26
$248 47 —
IBSRELA
  • Ardelyx, Inc. $92
$92 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $75
$75 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $69
$69 — —
RINVOQ
  • AbbVie, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record